Ethnic Difference in Hematological Toxicity in Patients with Non-small Cell Lung Cancer Treated with Chemotherapy: A Pooled Analysis on Asian versus Non-Asian in Phase II and III Clinical Trials-Reference-Cited by-同舟云学术

Ethnic Difference in Hematological Toxicity in Patients with Non-small Cell Lung Cancer Treated with Chemotherapy: A Pooled Analysis on Asian versus Non-Asian in Phase II and III Clinical Trials

Published:2011-11 Issue:11 Volume:6 Page:1881-1888
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Hasegawa Yoshikazu,Kawaguchi Tomoya,Kubo Akihito,Ando Masahiko,Shiraishi Junji,Isa Shun-ichi,Tsuji Taisuke,Tsujino Kazuyuki,Ou Sai-Hong I.,Nakagawa Kazuhiko,Takada Minoru

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference22 articles.

1. Common arm analysis: one approach to develop the basis for global standardization in clinical trials of non-small cell lung cancer;Sekine;Lung Cancer,2006

2. Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics;Gandara;J Clin Oncol,2009

3. Erlotinib in previously treated non-small-cell lung cancer;Shepherd;N Engl J Med,2005

4. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer);Thatcher;Lancet,2005

5. Ethnic differences in drug metabolism and toxicity from chemotherapy;Phan;Expert Opin Drug Metab Toxicol,2009

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study;The Lancet Oncology;2024-07

2. Paclitaxel therapeutic drug monitoring - International association of therapeutic drug monitoring and clinical toxicology recommendations;European Journal of Cancer;2024-05

3. Anti-lung Cancer Activity of Synthesized Substituted 1,4-Benzothiazines: An Insight from Molecular Docking and Experimental Studies;Anti-Cancer Agents in Medicinal Chemistry;2023-11-10

4. Comparison of safety outcomes of anticancer drugs in Japanese and non-Japanese patients in multi-regional clinical trials: meta-analysis of safety profiles;Investigational New Drugs;2023-05-10

5. Ethnic differences in lung cancer: “we can differ and still unite around common goals.”;Respiratory Investigation;2023-05